US Bioservices now dispenses VERZENIO

October 4, 2017

The U.S. Food and Drug Administration has approved VERZENIO (abemaciclib) in combination with fulvestrant for the treatment of women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer that has progressed after endocrine therapy. VERZENIO is also approved as a monotherapy for the treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.